[Disclosure] Alteogen (196170) to List 28,055 Additional Common Shares via Preferred Stock Conversion

Source Fact: Financial Supervisory Service DART / 2026-03-17

Disclosure Type: Additional Listing (Conversion of Preferred Stock into Common Stock)

💡 3-Second Summary

Alteogen will list an additional 28,055 common shares on March 20, 2026, following the conversion of previously issued convertible preferred stocks. The conversion price per share is KRW 356,433.

📊 1. [Key Disclosure Details & Figures Summary]

• Type & Number of Additional Shares: 28,055 common shares
• Reason for Listing: Conversion of preferred stock into common stock (117th issuance, converted on Feb 27, 2026)
• Conversion Price per Share: KRW 356,433
• Listing Date: March 20, 2026
• Total Outstanding Shares After Listing: Common shares will increase to a total of 53,533,843 shares
• Par Value per Share: KRW 500

📈 2. [Expert Insight: Stock Price Impact Analysis]

• Negligible Dilution, Minimal Overhang Risk: The 28,055 additional shares represent only about 0.052% of Alteogen’s total outstanding shares (approx. 53.53 million shares). Because the equity dilution profile is virtually non-existent, any negative impact or downward pressure on the stock price will be strictly contained.
• Implications of the KRW 356K Conversion Price: The conversion price is structurally locked at KRW 356,433 per share. This indicates that the convertible preferred stock (CPS) investors exercised their rights to convert based on their confidence in Alteogen’s mid-to-long-term Fundamental value. Given the relatively high benchmark price, it does not represent a toxic low-priced supply shock.
• Clearing Potential Overhang Volatility: While the float increases marginally, this conversion systematically reduces the pool of potential dilutive shares waiting in the wings, clearing minor capital structure uncertainties. This should be viewed as a neutral corporate disclosure with zero structural threat to the prevailing stock trend.

📝 Editor’s Comment (by K-STOCK Editor)

There is absolutely no reason to worry about a “dilution panic” upon seeing the additional listing headline. This represents a tiny fraction—less than 0.06% of total equity—and stems from a high-priced preferred stock conversion rather than a deeply discounted convertible bond (CB) dump. Treat March 20 as a routine backend listing date on the financial calendar, and keep your focus locked entirely on Alteogen’s core macroeconomic and R&D pipeline milestones.

📢 Disclaimer & Source Information

Source: This content was structured and generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.